- Vatalanib
Los M, Roodhart JM, Voest EE title Target practice lessons from phase III trials with bevacizumab ... more details
|
- John A. Boockvar
John A. Boockvar is an United States American neurosurgeon . He is an associate professor of neurosurgery, co director of Surgical Neuro Oncology, and director of the Brain Tumor and Stem Cell Research Laboratory at Weill Cornell Medical College in New York City . He is also a board certified adult neurosurgeon at New York Presbyterian Hospital . ref name mainpage http www.weillcornell.org jboockvar Weill Cornell Physicians John A. Boockvar , Biography page on Weill Cornell s website. ref Career Boockvar received a B.A. degree from the University of Pennsylvania and earned his M.D. degree from SUNY Downstate Medical Center in 1997. ref cite web url http www.aaf online.org php member area hb online cds live neuroS07 partic boockvar.htm title Open Medical Institute work aaf online.org accessdate 19 March 2012 ref He did a surgical internship and a neurosurgical residency at the University of Pennsylvania School of Medicine . He joined the staff at Weill Cornell Medical College in 2004. In 2005 he was named the first recipient of the Alvina and Willis Murphy Assistant Professorship of Neurological Surgery, an endowed position for a junior faculty member who has shown exceptional promise in the field of neurological surgery. ref name dean http weill.cornell.edu deans 2005 08 23 05 article 5 8 23.shtml New Assistant Professorships for Neurological Research and Medicine , Weill Cornell Dean s Bulletin, August 23, 2005 ref Practice In 2005 he was the first surgeon in the tri state area to implant the newly approved artificial spinal disc Charit into a patient. ref name dean ref http www.nytimes.com 2004 10 27 business 27disc.html Artificial Spinal Disk Gains Approval From the F.D.A. , New York Times, October 27, 2004 ref In 2009 he performed the world s first intra arterial delivery of the high potency chemotherapeutic agent Avastin bevacizumab directly into a malignant brain tumor . ref cite web url http www.sciencedaily.com releases 2009 11 091117102048.htm title World ... more details
|
- POEMS syndrome
syndrome, some have tried bevacizumab Avastin , a monoclonal antibody directed against VEGF. While ... Liewen F, et al. title Treatment of POEMS syndrome with bevacizumab journal Haematologica volume 92 ... more details
|
- Splenic infarction
4 pages 214 6 year 2006 month September pmid 16767537 doi 10.1007 s10194 006 0291 5 url ref or bevacizumab ... M title Splenic infarction and bevacizumab journal Lancet Oncol. volume 7 issue 12 pages 1038 year ... more details
|
- Tower Cancer Research Foundation
, ref A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced ... TPS298 Phase I study of danusertib D in combination with bevacizumab B in solid tumors. ASCO 2010 ... more details
|
- Large-cell lung carcinoma with rhabdoid phenotype
with VEGF blocking monoclonal antibodies such as bevacizumab may be active in these variants. ref ... phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel ... cite journal author Sandler A, Gray R, Perry MC, et al. title Paclitaxel carboplatin alone or with bevacizumab ... with either placebo or bevacizumab as first line therapy for nonsquamous non small cell lung ... the therapeutic use of bevacizumab , other anti VEGF compounds, or anti angiogenesis agents ... more details
|
- Glioblastoma multiforme
by concurrent or sequential chemoradiotherapy , antiangiogenic therapy with bevacizumab , gamma ... 008 9663 9 ref The U.S. Food and Drug Administration approved Avastin bevacizumab to treat patients ... and other cancers where bevacizumab acts by potentiating chemotherapy, the studies leading to approval showed that in GBM, the addition of chemotherapy to bevacizumab did not improve on results from bevacizumab alone. Bevacizumab reduces brain edema and consequent symptoms, and it may be that the benefit ... from that due to tumor, and both may coexist. Both respond to bevacizumab. Gene transfer ... more details
|
- Breast cancer treatment
Bevacizumab Avastin ramucirumab Monoclonal antibody AVADO ref http www.medicalnewstoday.com articles 131155.php Avastin R bevacizumab Now Approved For Use In Combination With Docetaxel For The First ... , bevacizumab , underwent testing in a randomized clinical trial whose preliminary results were announced by the National Cancer Institute in 2005. ref cite press release title Bevacizumab Combined With Chemotherapy ... accessdate 2007 08 15 ref The preliminary data indicated that bevacizumab delays disease progression ... , manufacturer of bevacizumab, has filed a supplemental biological application with the U.S. Food and Drug Administration US FDA for approval of bevacizumab in the setting of metastatic breast cancer ... more details
|
- ARMS2
of exudative age related macular degeneration to intravitreal bevacizumab. journal Ophthalmology ... more details
|
- HOHMS
no bevacizumab anti VEGF in cavitary or in near large vessels References See Wikipedia Footnotes on how ... more details
|
- Genentech
multifocal leukoencephalopathy . 2004 Bevacizumab Avastin bevacizumab Anti VEGF monoclonal antibody ... more details
|
- Macular degeneration
and regulatory agencies in other countries. The first major anti VEGF agent was bevacizumab Avastin , which was approved for use in cancer. Bevacizumab is a monoclonal antibody . Genentech , the manufacturer, developed bevacizumab into a smaller molecule, ranibizumab Lucentis , for use in the eye, and got ... GBP per treatment in the United Kingdom. ref name copleyreuters2012 Bevacizumab is packaged and used for cancer in larger doses than the doses used in the eye. Bevacizumab can be administered in smaller ... more details
|
- Combined small-cell lung carcinoma
HN title Effectiveness and safety of bevacizumab for unresectable non small cell lung cancer a meta ... 30&issue 4&spage 229 ref Bevacizumab Avastin ref name Avastin http www.avastin.com avastin patient ... and adenocarcinoma with mixed subtypes . ref name MotoiSzoke The role of VEGF inhibition and bevacizumab ... L, Dahlberg SE, Sandler AB, et al. title Phase II study of cisplatin plus etoposide and bevacizumab ... Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive ... more details
|
- Monoclonal antibody therapy
inihibition of B cell activating factor Systemic lupus erythematosus dn date November 2011 Bevacizumab ... antibodies on the market are bevacizumab , trastuzumab both oncology , adalimumab , infliximab ... more details
|
- White dot syndromes
antivascular endothelial growth factor VEGF agents. Examples are bevacizumab avastin and ranibizumab ... in this. The use of the intravitreal anti VEGF agents namely bevacizumab avastin and ranibizumab Lucentis ... more details
|
- Treatment of lung cancer
bevacizumab Avastin , in combination with paclitaxel and carboplatin , improves the survival of patients ... A coauthors Gray R, Perry M, et al. title Paclitaxel carboplatin alone or with bevacizumab for non ... more details
|
- Treatment and prognosis of renal cell carcinoma
proteins that promote inappropriate vascularization. Bevacizumab , an antibody to Vascular endothelial ... more details
|
- Proteinuria
SignSymptom infobox Name Proteinuria Image Caption DiseasesDB 25320 ICD10 ICD10 R 80 r 80 ICD9 ICD9 791.0 ICDO OMIM MedlinePlus eMedicineSubj med eMedicineTopic 94 MeshID D011507 Proteinuria IPAc en p r o t i n r i or IPAc en p r o t i nj r i from protein and urine means the presence of an excess of Blood plasma serum protein s in the urine . The excess protein in the urine often causes the urine to become foamy, although foamy urine may also be caused by bilirubin in the urine bilirubinuria , ref name Retrieved 2007 01 20 http www.pathguy.com lectures urine.htm URINALYSIS Ed Friedlander, M.D., Pathologist Retrieved 2007 01 20 ref retrograde ejaculation , ref http www.medhelp.org forums urology archive 195.html foamy urine Urology MedHelp Retrieved 2007 01 20 ref pneumaturia air bubbles in the urine due to a fistula , ref GPnotebook 1161101335 Pneumaturia Retrieved 2007 01 20 ref or drugs such as pyridium . ref name Retrieved 2007 01 20 Up to 150 mg a day of protein may be excreted by a normal person, primarily the Tamm Horsfall protein . Causes There are three main mechanisms to cause proteinuria Due to disease in glomerulus Because of increased quantity of proteins in blood serum serum overflow proteinuria Due to low reabsorption at proximal tubule fanconi syndrome fanconi Proteinuria can also be caused by certain biological agents, such as bevacizumab Avastin used in cancer treatment, or by excessive fluid intake drinking in excess of 4 litres of water per day . ref cite doi 10.1503 cmaj.070792 noedit ref ref cite news url http www.canada.com montrealgazette news story.html?id 378f85de 27de 4046 815e 293b772666e5 title Drinking too much water called latest threat to health date January 2008 publisher Montreal Gazette ref Measurement class wikitable align right colspan 3 Protein dipstick grading rowspan 2 Designation colspan 2 Approx. amount Concentration ref http emedicine.medscape.com article 984289 overview eMedicine Proteinuria Author Ronald J ... more details
|
- List of drugs: Be
United States Adopted Name USAN Bev Bez Bevacizumab International Nonproprietary Name INN Bevantolol ... more details
|
- Targeted therapy
lung cancer . Bevacizumab marketed as Avastin targets circulating VEGF ligand. It is approved for use ... more details
|
- Pseudoxanthoma elasticum
effect. Antiangiogenic drugs such as bevacizumab Avastin and ranibizumab Lucentis have been effective ... more details
|
- Pharmacoeconomics
. The The Food and Drug Administration withdrew approval for the use of Avastin Avastin Bevacizumab for breast ... more details
|
- Annual pharmaceutical drug sales
1,408.1 1,334.5 1,214.4 1,021.7 875 723 559.3 bevacizumab Avastin Metastatic colorectal cancer, non ... more details
|
- Carmen A. Puliafito
in the introduction of bevacizumab Avastin for the treatment of retinal disorders. He was the first ... more details
|
- Tumstatin
could be extremely beneficial. One study combined treatments of tumstatin with bevacizumab , or Avastin ... more details
|
Encyclopedia
top
